scholarly journals Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer

2022 ◽  
Vol 18 (1) ◽  
pp. 1-14
Author(s):  
Gianluca Aguiari ◽  
Francesca Crudele ◽  
Cristian Taccioli ◽  
Linda Minotti ◽  
Fabio Corrà ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Transglutaminase Type 2

scholarly journals Inhibition of the lncRNA Coded within Transglutaminase 2 Gene Impacts Several Relevant Networks in MCF-7 Breast Cancer Cells

2021 ◽  
Vol 7 (3) ◽  
pp. 49
Author(s):  
Carlo M. Bergamini ◽  
Chiara Vischioni ◽  
Gianluca Aguiari ◽  
Carmen Grandi ◽  
Anna Terrazzan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Epithelial Mesenchymal Transition ◽  
Human Cancer ◽  
Mesenchymal Transition ◽  
Human Cancer Cell Lines ◽  
Transglutaminase Type 2 ◽  
Mcf 7

Long non-coding RNAs are nucleotide molecules that regulate transcription in numerous cellular processes and are related to the occurrence of many diseases, including cancer. In this regard, we recently discovered a polyadenylated long non-coding RNA (named TG2-lncRNA) encoded within the first intron of the Transglutaminase type 2 gene (TGM2), which is related to tumour proliferation in human cancer cell lines. To better characterize this new biological player, we investigated the effects of its suppression in MCF-7 breast cancer cells, using siRNA treatment and RNA-sequencing. In this way, we found modifications in several networks associated to biological functions relevant for tumorigenesis (apoptosis, chronic inflammation, angiogenesis, immunomodulation, cell mobility, and epithelial–mesenchymal transition) that were originally attributed only to Transglutaminase type 2 protein but that could be regulated also by TG2-lncRNA. Moreover, our experiments strongly suggest the ability of TG2-lncRNA to directly interact with important transcription factors, such as RXRα and TP53, paving the way for several regulatory loops that can potentially influence the phenotypic behaviour of MCF-7 cells. These considerations imply the need to further investigate the relative relevance of the TG2 protein itself and/or other gene products as key regulators in the organization of breast cancer program.

scholarly journals The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 3059
Author(s):  
Nicoletta Bianchi ◽  
Federica Brugnoli ◽  
Silvia Grassilli ◽  
Karine Bourgeois ◽  
Jeffrey W. Keillor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Morphological Changes ◽  
Intracellular Localization ◽  
Nuclear Accumulation ◽  
Breast Cancer Cell Lines ◽  
Mesenchymal Transition ◽  
Transglutaminase Type 2 ◽  
Mcf 7

We have investigated motility in breast cancer cell lines in association with the expression of Transglutaminase type 2 (TG2) as well as upon the administration of Doxorubicin (Dox), an active cytotoxic agent that is employed in chemotherapy. The exposure of MCF-7 cells to the drug increased TG2 levels, triggering epithelial–mesenchymal transition (EMT), thereby supporting cell motility. The effects of Dox on the movement of MCF-7 cells were counteracted by treatment with NC9, a TG2 inhibitor, which induced morphological changes and also reduced the migration of MDA-MB-231 cells exhibiting high levels of TG2. The physical association of TG2 with the cytoskeletal component vimentin appeared pivotal both in drug-treated MCF-7 and in MDA-MB-231 cells and seemed to be independent of the catalytic activity of TG2. NC9 altered the subcellular distribution of TG2 and, consequently, the co-localization of TG2 with vimentin. Furthermore, NC9 induced a nuclear accumulation of TG2 as a prelude to TG2-dependent gene expression modifications. Since enzyme activity can affect both motility and nuclear functions, targeting of this protein could represent a method to improve therapeutic interventions in breast tumors, particularly those to control progression and to limit drug resistance.

scholarly journals Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tianli Hui ◽  
Chao Shang ◽  
Liu Yang ◽  
Meiqi Wang ◽  
Ruoyang Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cancer Patients ◽  
Invasive Breast Cancer ◽  
Breast Cancer Patients ◽  
Diabetes Group ◽  
Metformin Group

AbstractEarly reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan–Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.

scholarly journals PCN8 - SEVERITY OF BREAST CANCER ASSOCIATED WITH TYPE 2 DIABETES AND NOT WITH INSULIN TREATMENT

2018 ◽  
Vol 21 ◽  
pp. S16
Author(s):  
J.A. Overbeek ◽  
M.P. van Herk-Sukel ◽  
P.A. Vissers ◽  
A.A. van der Heijden ◽  
H.K. Bronsveld ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
Insulin Treatment

Herpesvirus Infections and Transglutaminase Type 2 Antibody Positivity in Childhood

2016 ◽  
Vol 63 (4) ◽  
pp. 423-430 ◽  
Author(s):  
Michelle A.E. Jansen ◽  
Diana van den Heuvel ◽  
Kirsten V.M. van der Zwet ◽  
Vincent W.V. Jaddoe ◽  
Albert Hofman ◽  
...  
Keyword(s):  
Transglutaminase Type 2 ◽  
Antibody Positivity

scholarly journals The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models

2015 ◽  
Vol 46 (6) ◽  
pp. 2335-2345 ◽  
Author(s):  
JUAN GARONA ◽  
MARINA PIFANO ◽  
ULISES D. ORLANDO ◽  
MARIA B. PASTRIAN ◽  
NANCY B. IANNUCCI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumour Growth ◽  
The Novel ◽  
Cancer Models

PO119 IMMUNE REACTIVITY IN PATIENTS WITH BREAST CANCER ASSOCIATED WITH TYPE 2 DIABETES MELLITUS

The Breast ◽  
2013 ◽  
Vol 22 ◽  
pp. S60
Author(s):  
Natalia Botnariuc ◽  
Larisa Sofroni ◽  
Vasile Jovmir ◽  
Diana Tcaciuc ◽  
Valentina Stratan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Immune Reactivity

scholarly journals Transglutaminase type 2: A multifunctional protein chaperone?

2014 ◽  
Vol 1 (4) ◽  
pp. e968506 ◽  
Author(s):  
Federica Rossin ◽  
Manuela D’Eletto ◽  
Maria Grazia Farrace ◽  
Mauro Piacentini
Keyword(s):  
Multifunctional Protein ◽  
Transglutaminase Type 2 ◽  
Protein Chaperone
Sign in / Sign up

Export Citation Format

Share Document